<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736227</url>
  </required_header>
  <id_info>
    <org_study_id>STU00201794</org_study_id>
    <nct_id>NCT02736227</nct_id>
  </id_info>
  <brief_title>Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation</brief_title>
  <official_title>Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most patients who get a liver transplant must take immunosuppressants for the rest of their&#xD;
      lives. However, this has occurred at the expense of chronic CNI toxicity, e.g. chronic kidney&#xD;
      disease (CKD), metabolic complications, infections and malignancy. Everolimus (EVL) is a drug&#xD;
      that may stabilize or improve kidney function for patients with chronic kidney disease (CKD)&#xD;
      that has been caused by immunosuppressants. EVL is used for standard of care treatment to&#xD;
      prevent transplant liver rejection in combination with other immunosuppressants, such as&#xD;
      tacrolimus. The overall aim of this study is to examine a combination of two different&#xD;
      immunosuppressants and EVL to determine if patients may have stabilized and/or improved&#xD;
      kidney function without liver rejection. This study will look at how safe it is to slowly&#xD;
      withdraw one anti-rejection medication while continuing to take the other medicine, and&#xD;
      whether this can be done without liver rejection occurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">March 2021</completion_date>
  <primary_completion_date type="Actual">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Treg cells and mRNA observed in peripheral blood prior to and during tacrolimus withdrawal plus everolimus treatment.</measure>
    <time_frame>Six months post transplantation</time_frame>
    <description>Sequential flow cytometry immunophenotyping and gene expression microassays</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Tacrolimus Withdrawal and Everolimus Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus will be tapered while continual use of everolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Withdrawal and Everolimus Monotherapy</intervention_name>
    <description>During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.</description>
    <arm_group_label>Tacrolimus Withdrawal and Everolimus Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult LT candidates â‰¥ 18 years of age&#xD;
&#xD;
          -  Listed for or recent (within 1 month) recipient of deceased or living donor liver&#xD;
             transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined or previous organ transplantation&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Inability to provide informed consent or comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh Levitsky, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Comprehensive Transplant Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Josh Levitsky</investigator_full_name>
    <investigator_title>Associate Professor in Medicine-Gastroenterology and Hepatology and Surgery-Organ Transplantation</investigator_title>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>everolimus</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>kidney function</keyword>
  <keyword>liver function</keyword>
  <keyword>biomarkers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

